DR. STEVEN GRANT, M.D.
Osteopathic Medicine at Marshall St, Richmond, VA

2006010, May 11, 2006

Sep 10, 2003

10/527553

Paul Dent - Glen Allen VA, US
Steven Grant - Richmond VA, US
Geoffrey Krystal - Richmond VA, US
Chunrong Yu - Rochester MN, US

A61K 38/12, A61K 31/506, A61K 31/405, A61K 31/19

514009000, 514252180, 514419000, 514557000, 514575000

The invention pertains to a combination of a histone deacetylase inhibitor and N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use for the treatment of leukemia and especially N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-resistant leukemia.

2006011, May 25, 2006

Jun 22, 2005

11/158743

Paul Fisher - Scarsdale NY, US
Rahul Gopalkrishnan - New York NY, US
Irina Lebedeva - Bronx NY, US
Steven Grant - Richmond VA, US
Adly Yacoub - Richmond VA, US
Paul Dent - Glen Allen VA, US

A61K 48/00

424093210, 514044000

The present invention relates to methods of treating a cancer in a subject comprising generating within one or more cancer cells of a subject an effective amount of MDA-7 and an effective amount of one or more free radicals. The present invention further relates to methods of inhibiting proliferation or promoting death in a cancer cell of a subject comprising generating within one or more cancer cells of a subject an effective amount of MDA-7 and an effective amount of one or more free radicals. Generation of an effective amount of MDA-7 can occur by administering to the cancer cell an effective amount of an mda-7 nucleic acid, MDA-7 protein, functional equivalents of either of these molecules, by upregulation of the endogenous mda-7 gene, or by stabilization of the mda-7 mRNA. Generation of one or more free radicals in a cancer cell can occur by exposing the cancer cell to an effective amount of ionizing radiation, a free radical, a generator of a free radical, a ROS, a generator of a ROS, or a disruptor of mitochondrial membrane potential.

2004019, Sep 30, 2004

Nov 4, 2003

10/363993

Paul Dent - Glen Allen VA, US
Steven Grant - Richmond VA, US
Robert McKinstry - Richmond VA, US
Yun Dai - Richmond VA, US
Chunrong Yu - Richmond VA, US

A61K051/00, A61K031/522

424/001490, 514/263310, 514/453000

The present invention provides a method for treating cancer by promoting apoptosis and reducing clonogenic survival of cancer cells. The method encompasses co-administering 1) a cell cycle checkpoint abrogation agent (for example, UCN-01 or caffeine) and 2) an inhibitor of a compensatory cytoprotective pathway, such as an agent that inhibits the MEK 1/2 pathway (e.g. PD98059, U0126, or PD184352) or an agent that inhibits the PI 3 pathway (e.g. LIY294002 or wortmanin). In addition, because the co-administration step also radiosensitizes cancer cells, the method additionally encompasses the administration of radiation to further reduce clonogenic survival of cancer cells. The method promotes apoptosis and reduces clonogenic survival in many types of cancer cells, including leukemia cells, prostate cancer cells, breast cancer cells, myeloma cells, and lymphoma cells.

7888341, Feb 15, 2011

Apr 4, 2003

10/510531

Paul Dent - GlenAllen VA, US
Steven Grant - Richmond VA, US
Geoffrey Krystal - Richmond VA, US
Chunrong Yu - Richmond VA, US

The United States of America as represented by the Department of Veterans Affairs - Washington DC
Virginia Commonwealth University - Richmond VA

A01N 43/58, A61K 31/50

514183, 514247

The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide and to its use for the treatment of cancer, especially of Bcr/Abl leukemia resistant to compound of formula I.

2009026, Oct 22, 2009

Jun 19, 2009

12/456669

Paul Dent - GlenAllen VA, US
Steven Grant - Richmond VA, US
Geoffrey Krystal - Richmond VA, US
Chunrong Yu - Rochester MN, US

A61K 31/497

51425218

The invention pertains to a combination of a histone deacetylase inhibitor and N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use for the treatment of leukemia and especially N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-resistant leukemia.

2009010, Apr 23, 2009

Jan 23, 2008

12/009867

Mitchell Keegan - Marlborough MA, US
Steven Grant - Richmond VA, US

A61K 31/56, A61K 31/395, C12N 5/02, A61P 35/04, A61K 31/4965

514171, 514431, 51425506, 435375

The invention provides a combination therapy for treating cancer and other neoplasms including romidepsin and a proteasome inhibitor. When administered together, romidepsin and a proteasome inhibitor (e.g., bortezomib) interact synergistically to selectively kill malignant cells at low (nanomolar) concentrations. The effect is particularly pronounced in malignant hematological cells (e.g., leukemia, lymphoma, multiple myeloma). The combination has also been found useful in treating bortezomib-resistant cancers and steroid-resistant cancers. The invention provides methods of killing malignant cells in vitro and in vivo. Pharmaceutical compositions, preparations, and kits including romidepsin and a proteasome inhibitor are also provided.